Epidemiological trends of pancreatic and gastrointestinal neuroendocrine tumors in Japan

a nationwide survey analysis

Tetsuhide Ito, Hisato Igarashi, Kazuhiko Nakamura, Hironobu Sasano, Takuji Okusaka, Koji Takano, Izumi Komoto, Masao Tanaka, Masayuki Imamura, Robert T. Jensen, Ryoichi Takayanagi, Akira Shimatsu

研究成果: ジャーナルへの寄稿記事

109 引用 (Scopus)

抄録

Background: Although neuroendocrine tumors (NETs) are rare, the number of patients with NET is increasing. However, in Japan, there have been no epidemiological studies on NET since 2005; thus, the prevalence of NET remains unknown.

Methods: We reported the epidemiology of gastroenteropancreatic neuroendocrine tumors (GEP-NETs) [pancreatic neuroendocrine tumors (PNETs) and gastrointestinal neuroendocrine tumors (GI-NETs)] in Japan in 2005. Here, we conducted the second nationwide survey on patients with GEP-NETs who received treatment in 2010.

Conclusion: We clarified the epidemiological changes in GEP-NETs from 2005 to 2010 in Japan.

Results: A total of 3,379 patients received treatment for PNETs in 2010, representing a 1.2-fold increase in the number of patients from 2005 to 2010. The prevalence was estimated to be 2.69/100,000, with an annual onset incidence of 1.27/100,000 in 2010. Non-functioning tumor (NF)-PNETs comprised 65.5 % of cases followed by insulinoma (20.9 %) and gastrinoma (8.2 %). Interestingly, the number of patients with NF-PNETs increased ~1.8 fold since 2005. A total of 19.9 % of patients exhibited distant metastasis at initial diagnosis; 4.3 % had complications with multiple endocrine neoplasia type 1 (MEN-1), and only 4.0 % had NF-PNETs associated with MEN-1. Meanwhile, an estimated 8,088 patients received treatment for GI-NETs, representing a ~1.8-fold increase since 2005. The prevalence was estimated to be 6.42/100,000, with an annual onset incidence of 3.51/100,000. The locations of GI-NETs varied: foregut, 26.1 %; midgut, 3.6 %; and hindgut, 70.3 %. Distant metastasis and complications with MEN-1 were observed in 6.0 and 0.42 % at initial diagnosis, respectively. The frequency of carcinoid syndrome in patients with GI-NETs was 3.2 %.

元の言語英語
ページ(範囲)58-64
ページ数7
ジャーナルJournal of gastroenterology
50
発行部数1
DOI
出版物ステータス出版済み - 1 1 2014

Fingerprint

Neuroendocrine Tumors
Japan
Multiple Endocrine Neoplasia Type 1
Surveys and Questionnaires
Gastrinoma
Neoplasm Metastasis
Neoplasms
Insulinoma
Incidence
Carcinoid Tumor
Epidemiologic Studies
Epidemiology
Therapeutics

All Science Journal Classification (ASJC) codes

  • Gastroenterology

これを引用

Epidemiological trends of pancreatic and gastrointestinal neuroendocrine tumors in Japan : a nationwide survey analysis. / Ito, Tetsuhide; Igarashi, Hisato; Nakamura, Kazuhiko; Sasano, Hironobu; Okusaka, Takuji; Takano, Koji; Komoto, Izumi; Tanaka, Masao; Imamura, Masayuki; Jensen, Robert T.; Takayanagi, Ryoichi; Shimatsu, Akira.

:: Journal of gastroenterology, 巻 50, 番号 1, 01.01.2014, p. 58-64.

研究成果: ジャーナルへの寄稿記事

Ito, T, Igarashi, H, Nakamura, K, Sasano, H, Okusaka, T, Takano, K, Komoto, I, Tanaka, M, Imamura, M, Jensen, RT, Takayanagi, R & Shimatsu, A 2014, 'Epidemiological trends of pancreatic and gastrointestinal neuroendocrine tumors in Japan: a nationwide survey analysis', Journal of gastroenterology, 巻. 50, 番号 1, pp. 58-64. https://doi.org/10.1007/s00535-014-0934-2
Ito, Tetsuhide ; Igarashi, Hisato ; Nakamura, Kazuhiko ; Sasano, Hironobu ; Okusaka, Takuji ; Takano, Koji ; Komoto, Izumi ; Tanaka, Masao ; Imamura, Masayuki ; Jensen, Robert T. ; Takayanagi, Ryoichi ; Shimatsu, Akira. / Epidemiological trends of pancreatic and gastrointestinal neuroendocrine tumors in Japan : a nationwide survey analysis. :: Journal of gastroenterology. 2014 ; 巻 50, 番号 1. pp. 58-64.
@article{a14a906e01554e3983941ac6b5b87a49,
title = "Epidemiological trends of pancreatic and gastrointestinal neuroendocrine tumors in Japan: a nationwide survey analysis",
abstract = "Background: Although neuroendocrine tumors (NETs) are rare, the number of patients with NET is increasing. However, in Japan, there have been no epidemiological studies on NET since 2005; thus, the prevalence of NET remains unknown.Methods: We reported the epidemiology of gastroenteropancreatic neuroendocrine tumors (GEP-NETs) [pancreatic neuroendocrine tumors (PNETs) and gastrointestinal neuroendocrine tumors (GI-NETs)] in Japan in 2005. Here, we conducted the second nationwide survey on patients with GEP-NETs who received treatment in 2010.Conclusion: We clarified the epidemiological changes in GEP-NETs from 2005 to 2010 in Japan.Results: A total of 3,379 patients received treatment for PNETs in 2010, representing a 1.2-fold increase in the number of patients from 2005 to 2010. The prevalence was estimated to be 2.69/100,000, with an annual onset incidence of 1.27/100,000 in 2010. Non-functioning tumor (NF)-PNETs comprised 65.5 {\%} of cases followed by insulinoma (20.9 {\%}) and gastrinoma (8.2 {\%}). Interestingly, the number of patients with NF-PNETs increased ~1.8 fold since 2005. A total of 19.9 {\%} of patients exhibited distant metastasis at initial diagnosis; 4.3 {\%} had complications with multiple endocrine neoplasia type 1 (MEN-1), and only 4.0 {\%} had NF-PNETs associated with MEN-1. Meanwhile, an estimated 8,088 patients received treatment for GI-NETs, representing a ~1.8-fold increase since 2005. The prevalence was estimated to be 6.42/100,000, with an annual onset incidence of 3.51/100,000. The locations of GI-NETs varied: foregut, 26.1 {\%}; midgut, 3.6 {\%}; and hindgut, 70.3 {\%}. Distant metastasis and complications with MEN-1 were observed in 6.0 and 0.42 {\%} at initial diagnosis, respectively. The frequency of carcinoid syndrome in patients with GI-NETs was 3.2 {\%}.",
author = "Tetsuhide Ito and Hisato Igarashi and Kazuhiko Nakamura and Hironobu Sasano and Takuji Okusaka and Koji Takano and Izumi Komoto and Masao Tanaka and Masayuki Imamura and Jensen, {Robert T.} and Ryoichi Takayanagi and Akira Shimatsu",
year = "2014",
month = "1",
day = "1",
doi = "10.1007/s00535-014-0934-2",
language = "English",
volume = "50",
pages = "58--64",
journal = "Journal of Gastroenterology",
issn = "0944-1174",
publisher = "Springer Japan",
number = "1",

}

TY - JOUR

T1 - Epidemiological trends of pancreatic and gastrointestinal neuroendocrine tumors in Japan

T2 - a nationwide survey analysis

AU - Ito, Tetsuhide

AU - Igarashi, Hisato

AU - Nakamura, Kazuhiko

AU - Sasano, Hironobu

AU - Okusaka, Takuji

AU - Takano, Koji

AU - Komoto, Izumi

AU - Tanaka, Masao

AU - Imamura, Masayuki

AU - Jensen, Robert T.

AU - Takayanagi, Ryoichi

AU - Shimatsu, Akira

PY - 2014/1/1

Y1 - 2014/1/1

N2 - Background: Although neuroendocrine tumors (NETs) are rare, the number of patients with NET is increasing. However, in Japan, there have been no epidemiological studies on NET since 2005; thus, the prevalence of NET remains unknown.Methods: We reported the epidemiology of gastroenteropancreatic neuroendocrine tumors (GEP-NETs) [pancreatic neuroendocrine tumors (PNETs) and gastrointestinal neuroendocrine tumors (GI-NETs)] in Japan in 2005. Here, we conducted the second nationwide survey on patients with GEP-NETs who received treatment in 2010.Conclusion: We clarified the epidemiological changes in GEP-NETs from 2005 to 2010 in Japan.Results: A total of 3,379 patients received treatment for PNETs in 2010, representing a 1.2-fold increase in the number of patients from 2005 to 2010. The prevalence was estimated to be 2.69/100,000, with an annual onset incidence of 1.27/100,000 in 2010. Non-functioning tumor (NF)-PNETs comprised 65.5 % of cases followed by insulinoma (20.9 %) and gastrinoma (8.2 %). Interestingly, the number of patients with NF-PNETs increased ~1.8 fold since 2005. A total of 19.9 % of patients exhibited distant metastasis at initial diagnosis; 4.3 % had complications with multiple endocrine neoplasia type 1 (MEN-1), and only 4.0 % had NF-PNETs associated with MEN-1. Meanwhile, an estimated 8,088 patients received treatment for GI-NETs, representing a ~1.8-fold increase since 2005. The prevalence was estimated to be 6.42/100,000, with an annual onset incidence of 3.51/100,000. The locations of GI-NETs varied: foregut, 26.1 %; midgut, 3.6 %; and hindgut, 70.3 %. Distant metastasis and complications with MEN-1 were observed in 6.0 and 0.42 % at initial diagnosis, respectively. The frequency of carcinoid syndrome in patients with GI-NETs was 3.2 %.

AB - Background: Although neuroendocrine tumors (NETs) are rare, the number of patients with NET is increasing. However, in Japan, there have been no epidemiological studies on NET since 2005; thus, the prevalence of NET remains unknown.Methods: We reported the epidemiology of gastroenteropancreatic neuroendocrine tumors (GEP-NETs) [pancreatic neuroendocrine tumors (PNETs) and gastrointestinal neuroendocrine tumors (GI-NETs)] in Japan in 2005. Here, we conducted the second nationwide survey on patients with GEP-NETs who received treatment in 2010.Conclusion: We clarified the epidemiological changes in GEP-NETs from 2005 to 2010 in Japan.Results: A total of 3,379 patients received treatment for PNETs in 2010, representing a 1.2-fold increase in the number of patients from 2005 to 2010. The prevalence was estimated to be 2.69/100,000, with an annual onset incidence of 1.27/100,000 in 2010. Non-functioning tumor (NF)-PNETs comprised 65.5 % of cases followed by insulinoma (20.9 %) and gastrinoma (8.2 %). Interestingly, the number of patients with NF-PNETs increased ~1.8 fold since 2005. A total of 19.9 % of patients exhibited distant metastasis at initial diagnosis; 4.3 % had complications with multiple endocrine neoplasia type 1 (MEN-1), and only 4.0 % had NF-PNETs associated with MEN-1. Meanwhile, an estimated 8,088 patients received treatment for GI-NETs, representing a ~1.8-fold increase since 2005. The prevalence was estimated to be 6.42/100,000, with an annual onset incidence of 3.51/100,000. The locations of GI-NETs varied: foregut, 26.1 %; midgut, 3.6 %; and hindgut, 70.3 %. Distant metastasis and complications with MEN-1 were observed in 6.0 and 0.42 % at initial diagnosis, respectively. The frequency of carcinoid syndrome in patients with GI-NETs was 3.2 %.

UR - http://www.scopus.com/inward/record.url?scp=84893194219&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84893194219&partnerID=8YFLogxK

U2 - 10.1007/s00535-014-0934-2

DO - 10.1007/s00535-014-0934-2

M3 - Article

VL - 50

SP - 58

EP - 64

JO - Journal of Gastroenterology

JF - Journal of Gastroenterology

SN - 0944-1174

IS - 1

ER -